Cargando…

The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients

BACKGROUND: Active surveillance (AS) is a promising option for patients with low-risk prostate cancer (PCa), however current criteria could not select the patients correctly, many patients who fulfilled recent AS criteria experienced pathological Gleason score upgrade (PGU) after radical prostatecto...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jong Jin, Park, Seunghyun, Lee, Sang Eun, Hong, Sung Kyu, Lee, Sangchul, Choe, Gheeyoung, Yoon, Sungroh, Byun, Seok-soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122442/
https://www.ncbi.nlm.nih.gov/pubmed/25093842
http://dx.doi.org/10.1371/journal.pone.0104146
_version_ 1782329353632219136
author Oh, Jong Jin
Park, Seunghyun
Lee, Sang Eun
Hong, Sung Kyu
Lee, Sangchul
Choe, Gheeyoung
Yoon, Sungroh
Byun, Seok-soo
author_facet Oh, Jong Jin
Park, Seunghyun
Lee, Sang Eun
Hong, Sung Kyu
Lee, Sangchul
Choe, Gheeyoung
Yoon, Sungroh
Byun, Seok-soo
author_sort Oh, Jong Jin
collection PubMed
description BACKGROUND: Active surveillance (AS) is a promising option for patients with low-risk prostate cancer (PCa), however current criteria could not select the patients correctly, many patients who fulfilled recent AS criteria experienced pathological Gleason score upgrade (PGU) after radical prostatectomy (RP). In this study, we aimed to develop an accurate model for predicting PGU among low-risk PCa patients by using exome genotyping. METHODS: We genotyped 242,221 single nucleotide polymorphisms (SNP)s on a custom HumanExome BeadChip v1.0 (Illuminam Inc.) in blood DNA from 257 low risk PCa patients (PSA <10 ng/ml, biopsy Gleason score (GS) ≤6 and clinical stage ≤T2a) who underwent radical prostatectomy. Genetic data were analyzed using an unconditional logistic regression to calculate an odds ratio as an estimate of relative risk of PGU, which defined pathologic GS above 7. Among them, we selected persistent SNPs after multiple testing using FDR method, and we compared accuracies from the multivariate logistic model incorporating clinical factors between included and excluded selected SNP information. RESULTS: After analysis of exome genotyping, 15 SNPs were significant to predict PGU in low risk PCa patients. Among them, one SNP – rs33999879 remained significant after multiple testing. When a multivariate model incorporating factors in Epstein definition – PSA density, biopsy GS, positive core number, tumor per core ratio and age was devised for the prediction of PGU, the predictive accuracy of the multivariate model was 78.4% (95%CI: 0.726–0.834). By addition the factor of rs33999879 in aforementioned multivariate model, the predictive accuracy was 82.9%, which was significantly increased (p = 0.0196). CONCLUSION: The rs33999879 SNP is a predictor for PGU. The addition of genetic information from the exome sequencing effectively enhanced the predictive accuracy of the multivariate model to establish suitable active surveillance criteria.
format Online
Article
Text
id pubmed-4122442
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41224422014-08-12 The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients Oh, Jong Jin Park, Seunghyun Lee, Sang Eun Hong, Sung Kyu Lee, Sangchul Choe, Gheeyoung Yoon, Sungroh Byun, Seok-soo PLoS One Research Article BACKGROUND: Active surveillance (AS) is a promising option for patients with low-risk prostate cancer (PCa), however current criteria could not select the patients correctly, many patients who fulfilled recent AS criteria experienced pathological Gleason score upgrade (PGU) after radical prostatectomy (RP). In this study, we aimed to develop an accurate model for predicting PGU among low-risk PCa patients by using exome genotyping. METHODS: We genotyped 242,221 single nucleotide polymorphisms (SNP)s on a custom HumanExome BeadChip v1.0 (Illuminam Inc.) in blood DNA from 257 low risk PCa patients (PSA <10 ng/ml, biopsy Gleason score (GS) ≤6 and clinical stage ≤T2a) who underwent radical prostatectomy. Genetic data were analyzed using an unconditional logistic regression to calculate an odds ratio as an estimate of relative risk of PGU, which defined pathologic GS above 7. Among them, we selected persistent SNPs after multiple testing using FDR method, and we compared accuracies from the multivariate logistic model incorporating clinical factors between included and excluded selected SNP information. RESULTS: After analysis of exome genotyping, 15 SNPs were significant to predict PGU in low risk PCa patients. Among them, one SNP – rs33999879 remained significant after multiple testing. When a multivariate model incorporating factors in Epstein definition – PSA density, biopsy GS, positive core number, tumor per core ratio and age was devised for the prediction of PGU, the predictive accuracy of the multivariate model was 78.4% (95%CI: 0.726–0.834). By addition the factor of rs33999879 in aforementioned multivariate model, the predictive accuracy was 82.9%, which was significantly increased (p = 0.0196). CONCLUSION: The rs33999879 SNP is a predictor for PGU. The addition of genetic information from the exome sequencing effectively enhanced the predictive accuracy of the multivariate model to establish suitable active surveillance criteria. Public Library of Science 2014-08-05 /pmc/articles/PMC4122442/ /pubmed/25093842 http://dx.doi.org/10.1371/journal.pone.0104146 Text en © 2014 Oh et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Oh, Jong Jin
Park, Seunghyun
Lee, Sang Eun
Hong, Sung Kyu
Lee, Sangchul
Choe, Gheeyoung
Yoon, Sungroh
Byun, Seok-soo
The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients
title The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients
title_full The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients
title_fullStr The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients
title_full_unstemmed The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients
title_short The Use of Exome Genotyping to Predict Pathological Gleason Score Upgrade after Radical Prostatectomy in Low-Risk Prostate Cancer Patients
title_sort use of exome genotyping to predict pathological gleason score upgrade after radical prostatectomy in low-risk prostate cancer patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4122442/
https://www.ncbi.nlm.nih.gov/pubmed/25093842
http://dx.doi.org/10.1371/journal.pone.0104146
work_keys_str_mv AT ohjongjin theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT parkseunghyun theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT leesangeun theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT hongsungkyu theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT leesangchul theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT choegheeyoung theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT yoonsungroh theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT byunseoksoo theuseofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT ohjongjin useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT parkseunghyun useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT leesangeun useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT hongsungkyu useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT leesangchul useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT choegheeyoung useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT yoonsungroh useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients
AT byunseoksoo useofexomegenotypingtopredictpathologicalgleasonscoreupgradeafterradicalprostatectomyinlowriskprostatecancerpatients